Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Li-Ping Yang, Zhi-Wei Zhou, Xiao-Wu Chen, Chun Guang Li, Kevin B. Sneed, Jun Liang & Shu-Feng Zhou. (2012) Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. Xenobiotica 42:3, pages 238-255.
Read now
Read now
Shu-Feng Zhou, Bo Wang, Li-Ping Yang & Jun-Ping Liu. (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews 42:2, pages 268-354.
Read now
Read now
F. Fratev, E. Lo Piparo, E. Benfenati & E. Mihaylova. (2007) Toxicity study of allelochemical-like pesticides by a combination of 3D-QSAR, docking, Local Binding Energy (LBE) and GRID approaches. SAR and QSAR in Environmental Research 18:7-8, pages 675-692.
Read now
Read now
Articles from other publishers (18)
N. M. Raghavendra, B. R. Prashantha Kumar, Pujan Sasmal, Ghanshyam Teli, Rohit Pal, P. M. Gurubasavaraja Swamy & B. Sajeev Kumar. 2023. The Quintessence of Basic and Clinical Research and Scientific Publishing. The Quintessence of Basic and Clinical Research and Scientific Publishing
125
148
.
Richard LonsdaleRachel M. FortPatrik Rydberg, Jeremy N. HarveyAdrian J. Mulholland. (2016) Quantum Mechanics/Molecular Mechanics Modeling of Drug Metabolism: Mexiletine N-Hydroxylation by Cytochrome P450 1A2. Chemical Research in Toxicology 29:6, pages 963-971.
Crossref
Crossref
Rui Gu, David E. Hibbs, Jennifer A. Ong, Robert J. Edwards & Michael Murray. (2014) The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochemical Pharmacology 88:2, pages 245-252.
Crossref
Crossref
Satoshi Yamaori, Yoshimi Okushima, Kazufumi Masuda, Mika Kushihara, Takashi Katsu, Shizuo Narimatsu, Ikuo Yamamoto & Kazuhito Watanabe. (2013) Structural Requirements for Potent Direct Inhibition of Human Cytochrome P450 1A1 by Cannabidiol: Role of Pentylresorcinol Moiety. Biological and Pharmaceutical Bulletin 36:7, pages 1197-1203.
Crossref
Crossref
Joanne Siok Liu Lim, Onkar Singh, Rathi Devi Ramasamy, Saminathan Ramasamy, Koilan Subramanian, Edmund J.D. Lee & Balram Chowbay. (2010) Pharmacogenetics of CYP1A2, Novel Polymorphisms and Haplotypes in Three Distinct Asian Populations. Drug Metabolism and Pharmacokinetics 25:6, pages 616-623.
Crossref
Crossref
Shu-Feng Zhou, Li-Ping Yang, Zhi-Wei Zhou, Ya-He Liu & Eli Chan. (2009) Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2. The AAPS Journal 11:3, pages 481-494.
Crossref
Crossref
Filip Fratev & Emilio Benfenati. (2008) A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. Journal of Molecular Graphics and Modelling 27:2, pages 147-160.
Crossref
Crossref
David F. V. Lewis, Brian G. Lake & Maurice Dickins. (2008) Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: The importance of compound lipophilicity. Journal of Enzyme Inhibition and Medicinal Chemistry 22:1, pages 1-6.
Crossref
Crossref
Andreas Matusch, Philipp T. Meyer, Dirk Bier, Marcus H. Holschbach, Dirk Woitalla, David Elmenhorst, Oliver H. Winz, Karl Zilles & Andreas Bauer. (2006) Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nuclear Medicine and Biology 33:7, pages 891-898.
Crossref
Crossref
David F.V. Lewis, Yuko Ito & Brian G. Lake. (2006) Metabolism of coumarin by human P450s: A molecular modelling study. Toxicology in Vitro 20:2, pages 256-264.
Crossref
Crossref
James W Paxton, Philip Kestell, Daniel Chiang, Shufeng Zhou & David FV Lewis. (2005) INHIBITION OF HUMAN CYP1A2 OXIDATION OF 5,6‐DIMETHYL‐XANTHENONE‐4‐ACETIC ACID BY ACRIDINES: A MOLECULAR MODELLING STUDY. Clinical and Experimental Pharmacology and Physiology 32:8, pages 633-639.
Crossref
Crossref
F. Iori, R. da Fonseca, M. João Ramos & M.C. Menziani. (2005) Theoretical quantitative structure–activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorganic & Medicinal Chemistry 13:14, pages 4366-4374.
Crossref
Crossref
Akiko Soyama, Yoshiro Saito, Nobumitsu Hanioka, Keiko Maekawa, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kazuyuki Ueno, Yu-ichi Goto, Hideo Kimura, Masaaki Katoh, Kenji Sugai, Osamu Saitoh, Mitsuru Kawai, Teiichi Ohnuma, Taisuke Ohtsuki, Chieko Suzuki, Narihiro Minami, Naoyuki Kamatani, Shogo Ozawa & Jun-ichi Sawada. (2005) Single Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population. Drug Metabolism and Pharmacokinetics 20:1, pages 24-33.
Crossref
Crossref
Carol A. Kemp, Jean-Didier Maréchal & Michael J. Sutcliffe. (2005) Progress in cytochrome P450 active site modeling. Archives of Biochemistry and Biophysics 433:2, pages 361-368.
Crossref
Crossref
David E. Clark. 2005.
133
151
.
Alexander Hillisch, Luis Felipe Pineda & Rolf Hilgenfeld. (2004) Utility of homology models in the drug discovery process. Drug Discovery Today 9:15, pages 659-669.
Crossref
Crossref
Norie Murayama, Akiko Soyama, Yoshiro Saito, Yukiko Nakajima, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Hideo Kimura, Yu-ichi Goto, Osamu Saitoh, Masaaki Katoh, Teiichi Ohnuma, Mitsuru Kawai, Kenji Sugai, Taisuke Ohtsuki, Chieko Suzuki, Narihiro Minami, Shogo Ozawa & Jun-ichi Sawada. (2004)
Six Novel Nonsynonymous
CYP1A2
Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes
. Journal of Pharmacology and Experimental Therapeutics 308:1, pages 300-306.
Crossref
Crossref
Ming-Jaw Don, David F.V. Lewis, Shu-Yun Wang, Mei-Wen Tsai & Yune-Fang Ueng. (2003) Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorganic & Medicinal Chemistry Letters 13:15, pages 2535-2538.
Crossref
Crossref